Commercialisation
Dr Herbert is a protein biochemist with over 39 years of experience in technology development and commercialisation and has co-founded two ASX listed companies in the biotech/healthcare industry. He has broad experience in securing investment for companies in the biotech/healthcare industry and a track record of creating, protecting, and commercialising intellectual property. He has developed and commercialised biotechnology products with multinational partners, such as Bio-Rad and Sigma-Aldrich, and his co-founded companies – Proteome Systems, Regeneus and Sangui Bio.
​
In 1999, he co-founded the biotechnology company Proteome Systems, where he served full time as Head of Sample Preparation until 2006. He played an active role in establishing and managing Proteome Systems IP portfolio.
​
In 2007 Ben was a co-founder of Regeneus Ltd, a regenerative medicine company that has developed and commercialised stem cell therapies using adipose derived cells. Ben served as a non-executive Director of Regeneus from startup through ASX listing in 2013 and left the Board to pursue the opportunities that became Sangui Bio in late 2014.
Intellectual Property
Dr Herbert has numerous patents and pending applications. These are primarily focused on new technologies and methodologies for the analysis and therapeutic manipulation of blood and its components, particularly red blood cells and proteins. Key themes include novel devices and methods for microsampling, blood preparation and protein profiling, and the use of biomarkers for monitoring disease progression, particularly in the context of cell therapy.
Research Impact and Contribution
Ben Herbert has 39 years of experience in protein chemistry, sample preparation, fractionation, and proteomics. He has gained international recognition as one of key innovators in sample preparation, fractionation and the use of proteomics. Ben has over 100 research, review papers and book chapters. His research papers and chapters have been cited 7400 times and his H-index measurement of research impact is 41. Dr Herbert has supervised 9 PhD students to completion and currently co-supervises 1 PhD student.